Fluvoxamine alone in the treatment of delusional depression

American Journal of Psychiatry

Volumn 153, Issue 3, 1996, Pages 414-416

  Gatti, Flavia ^a   Bellini, Laura ^a   Gasperini, Mariangela ^a   Perez, Jorge ^a   Zanardi, Raffaella ^a   Smeraldi, Enrico ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; FLUVOXAMINE;

ADULT; ARTICLE; DELUSION; DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; RATING SCALE; TREATMENT PLANNING;

EID: 0029883517     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.3.414     Document Type: Article

References (12)

1. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F: Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992; 24:17-24
2. Anderson IM, Tomenson BM: The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacology 1994; 8:238-249
3. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT: Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54:338-342
4. Bellini L, Gasperini M, Gatti F, Franchini L, Smeraldi E: A double-blind study with fluvoxamine versus desipramine combined with placebo or haloperidol in delusional depression, in Critical Issues in the Treatment of Affective Disorders: International Academy for Biomedical and Drug Research, vol 9. Edited by Langer SZ, Mendlewicz J, Racagni G. Basel, Switzerland, Karger, 1995, pp 32-36
5. Kendler KS, Glazer WM, Morgenstern H: Dimensions of delusional experience. Am J Psychiatry 1983; 140:466-469
6. Glassman AH, Roose SP: Delusional depression: a distinct clinical entity? Arch Gen Psychiatry 1981; 38:424-427
7. Ottavenger EA: The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:731-739
8. Kupfer DJ, Frank E, Perel JM: Advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989; 46:771-775
9. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO: A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985; 19:57-64
10. Ferré S, Cortés R, Artigas F: Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci 1994; 14:4839-4846
11. Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:717-725
12. Smeraldi E, Cavallaro R, Di Rosa M, Della Maggiore P, Brancato V: Prevalence and risk factors of involuntary movement disorders in a neuroleptic-treated population: a comparison between schizophrenic spectrum and non-schizophrenic spectrum patients. Schizophr Res 1991; 4:367-368